FDA panel: Endo opioid painkiller's risks outweigh its benefits
A Food and Drug Administration panel found, in an 18-8 vote, that the benefits of a newer formulation of Endo International ’s Opana ER — an extended-release, opioid pain medicine — no longer outweigh its risks.
The FDA’s Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees is reviewing oxymorphone products such as Opana ER because of the high abuse rate of such medicines. The FDA will make the final decision on whether to take any regulatory action…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: John George Source Type: news
More News: Anesthesia | Anesthesiology | Food and Drug Administration (FDA) | Health Management | Hospital Management | Opana | Pain | Pain Management | Substance Abuse